Chronic Pain, Pain
Conditions
Keywords
Genetic Variation, Genetic Polymorphism, Polymorphism, Single Nucleotide, Genetic Association Studies
Brief summary
The purpose of this study is to (a) evaluate the treatment approaches and changes in treatment regimens utilized by clinicians when genetic testing is performed in the clinic; and (b) create a patient data registry to identify genetic factors that influence treatment outcomes in pain management.
Detailed description
Clinicians who treat pain have noted that the response to opioids and other pain medications varies widely among patients. Differences in the degree of pain stimulation and pain sensitivity, weight and age differences, prior opioid use and tolerance, as well as the differences in bioavailability of various opioid formulations have been cited as causes for the wide variability in analgesia seen with opioids. However, a significant component of chronic pain may also be explained by genetic polymorphisms. Genetic information may explain the variability of responses and help predict more effective (or less dangerous) treatments and medication choices and doses. By identifying the genetic risks and the most effective analgesic for an individual patient, clinicians may be able to improve the efficacy of the pain treatments and medications and decrease the risk of iatrogenically-induced overdose, addiction, and death. The purpose of this study is to evaluate how currently available genetic tests are being implemented in a pain management setting and whether this information results in benefits to patient care. Chronic pain patients receiving routine medical visits for their care will complete validated questionnaires to measure pain levels, disability indices, mental health, and quality of life measurements at each clinical visit. Physicians will document any changes made to treatment regimens, including adjustments to medications or non-pharmacological treatments and improvements in pain, functional ratings, or patient satisfaction. Concomitantly, this study will use the collected genetic and clinical data to create a data registry in order to examine novel correlations and associations between single nucleotide polymorphisms and longitudinal datasets. The results of this study will elucidate potential predictive variables of chronic pain development and/or treatment that will assist in making better healthcare decisions in the selection of treatment modalities and dosing of medications for chronic pain.
Interventions
OTHERObservational
Observational Study only
Sponsors
University of Southern California
Proove Bioscience, Inc.
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Provide signed and dated informed consent form. * Willing to comply with all study procedures and be available for the duration of the study. * Currently experiencing a chronic pain problem, with symptoms that have occurred within the last 30 days.
Exclusion criteria
* Severe hepatic or renal disease * Significant diminished mental capacity that is unable to understand the protocol, surveys and questionnaires; unable to read/write English or Spanish * Recent febrile illness that precludes or delays participation by more than 1 month * Pregnancy or lactation * Participation in a clinical study that may interfere with participation in this study * Anything that would place the individual at increased risk or preclude the individual's full compliance with or completion of the study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Changes in the frequency of urine drug screens | Up to 5 years | — |
| Pain Scores on the Pain Numeric Rating Scale (NRS) | Up to 2 years | — |
| Pain Scores on the CSS-17 | Up to 2 years | The Chronic Regional Pain Syndrome (CRPS) Severity Score (CSS-17) is used for patients with CRPS. |
| Function/Disability assessment on the Oswestry Disability Index (ODI) | Up to 2 years | The ODI is used for patients with back or neck pain. |
| Function/Disability assessment on the Headache Impact Test (HIT-6) | Up to 2 years | The HIT-6 is used for patients with headaches or migraines. |
| Health-Related Quality of Life assessment on the SF-12v2 | Up to 2 years | The Short Form 12 item-version 2 (SF-12v2) is a generic assessment of health-related quality of life. |
| Presence and Severity of Generalized Anxiety Disorder on the GAD-2/GAD-7 | Up to 2 years | The GAD-2 short screening tool consists of the first two questions of the GAD-7 scale. |
| Presence and Severity of Depression on the PHQ-2/PHQ-9 | Up to 2 years | The PHQ-2 is a short screening tool for the PHQ-9. |
| Number of Participants that Experience of Adverse Events | Up to 5 years | — |
| Type of Adverse Events Experienced by Participants | Up to 5 years | — |
| Severity of Adverse Events Experienced by Participants | Up to 5 years | — |
| Changes in type of treatments selected for participants | Up to 5 years | — |
| Changes in medication dosage for the participants | Up to 5 years | — |
Secondary
| Measure | Time frame |
|---|---|
| The Session Rating Scale as a measure of the Patient-provider alliance | Up to 2 years |
Countries
United States
Outcome results
None listed